Belite Bio Management
Management criteria checks 2/4
Belite Bio's CEO is Tom Lin, appointed in Nov 2021, has a tenure of 6.67 years. directly owns 1.72% of the company’s shares, worth $42.66M. The average tenure of the management team and the board of directors is 3 years and 3 years respectively.
Key information
Tom Lin
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 3yrs |
| CEO ownership | 1.7% |
| Management average tenure | 3yrs |
| Board average tenure | 3yrs |
Recent management updates
Recent updates
We're Interested To See How Belite Bio (NASDAQ:BLTE) Uses Its Cash Hoard To Grow
Sep 26
Are Investors Undervaluing Belite Bio, Inc (NASDAQ:BLTE) By 45%?
Jul 03We're Hopeful That Belite Bio (NASDAQ:BLTE) Will Use Its Cash Wisely
Mar 20An Intrinsic Calculation For Belite Bio, Inc (NASDAQ:BLTE) Suggests It's 49% Undervalued
Jan 10Belite Bio, Inc's (NASDAQ:BLTE) Intrinsic Value Is Potentially 25% Below Its Share Price
Jul 31We're Not Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn
May 03Belite Bio down 21% after disappointing mid-stage results of rare eye disease candidate
Oct 03Belite Bio receives approval of begin LBS-008 phase 3 trial in China
Sep 16Belite Bio adds 15% as pivotal trial for lead asset starts in U.S.
Aug 22Belite Bio GAAP EPS of -$0.23 beats by $0.05
Aug 12Belite Bio (NASDAQ:BLTE) Is In A Good Position To Deliver On Growth Plans
Aug 01Belite seeks FDA nod to proceed with phase 3 trial of genetic eye disease treatment
Jul 19CEO
Tom Lin (45 yo)
3yrs
Tenure
Dr. Yu-Hsin Lin, also known as Tom, MBA MMed PhD (Med) is the founder and has served as Director of Belite Bio Inc since March 2018 and its Chairman and served as the Chief Executive Officer since November...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board of Directors & CEO | 3yrs | no data | 1.72% $ 42.7m | |
| CFO & Director | 4.6yrs | no data | 1.01% $ 25.0m | |
| Chief Scientific Officer | 3yrs | no data | no data | |
| Chief Medical Officer & Member of Ophthalmology Clinical Advisory Board | less than a year | no data | no data |
3.0yrs
Average Tenure
45yo
Average Age
Experienced Management: BLTE's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board of Directors & CEO | 6.7yrs | no data | 1.72% $ 42.7m | |
| CFO & Director | 3yrs | no data | 1.01% $ 25.0m | |
| Chief Medical Officer & Member of Ophthalmology Clinical Advisory Board | no data | no data | no data | |
| Member of Ophthalmology Clinical Advisory Board | no data | no data | no data | |
| Independent Director | 2.6yrs | no data | no data | |
| Member of Ophthalmology Clinical Advisory Board | no data | no data | no data | |
| Member of Ophthalmology Clinical Advisory Board | no data | no data | no data | |
| Director | 3yrs | no data | no data | |
| Director | 3yrs | no data | no data | |
| Independent Director | 2.6yrs | no data | no data | |
| Independent Director | 2.6yrs | no data | no data | |
| Member of Ophthalmology Clinical Advisory Board | no data | no data | no data |
3.0yrs
Average Tenure
45yo
Average Age
Experienced Board: BLTE's board of directors are considered experienced (3 years average tenure).